Surrozen, Inc.
NASDAQSurrozen reported Q1 2026 results after the close on May 6, delivering a headline EPS miss that would ordinarily send a clinical-stage biotech sharply lower — yet the setup heading into the print was notably bullish, and the stock had already moved hard in anticipation. The EPS miss is difficult to dismiss. Surrozen posted -$11.65 per share against a consensus estimate of -$1.09, a…
Snapshot as of 7 May 2026
Surrozen reported Q1 2026 results after the close on May 6, delivering a headline EPS miss that would ordinarily send a clinical-stage biotech sharply lower — yet the setup heading into the print was notably bullish,…
SRZN heads into the post-print session carrying a rare contradiction: fresh institutional conviction, visible insider exits, and a Q1 EPS miss that dwarfs any prior consensus estimate. The earnings release, filed…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SRZN — free to start on ORTEX.
Sign up for free →Open SRZN on ORTEX